Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyell ImmunopharmaLYEL +5.91%53 PS Ratio is 6,860.00 as of Jul. 30, 2026, which is 321% above its 10-year median of 1,630.00. GuruFocus rates LYEL with a GF Score™ of 53/100 and a GF Value™ of $5.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, Lyell Immunopharma ranks worse than 99.46% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lyell Immunopharma's share price is $13.72.
Lyell Immunopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Lyell Immunopharma's PS Ratio for today is 6,860.00.
The historical rank and industry rank for Lyell Immunopharma's PS Ratio or its related term are showing as below:
LYEL'
s PS Ratio Range Over the Past 10 Years
Min: 5.83 Med: 1630 Max: 14490
Current: 6860
During the past 7 years, Lyell Immunopharma's highest PS Ratio was 14490.00. The lowest was 5.83. And the median was 1630.00.
LYEL's PS Ratio is ranked worse than 99.46% of 930
companies
in the Biotechnology industry
Industry Median: 8.89
vs LYEL: 6860.00
Lyell Immunopharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Lyell Immunopharma was -60.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -93.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -78.20% per year.
During the past 7 years, Lyell Immunopharma's highest 3-Year average Revenue per Share Growth Rate was 380.00% per year. The lowest was -93.40% per year. And the median was -80.70% per year.
Back to Basics: PS Ratio
Lyell Immunopharma (NAS:LYEL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lyell Immunopharma PS Ratio Related Terms
Lyell Immunopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lyell Immunopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lyell Immunopharma's Share Price of today is $13.72. Lyell Immunopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lyell Immunopharma (LYEL) has a PS Ratio of 6,860.00 as of Jul. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lyell Immunopharma and its competitors. This is 321% above median its historical median of 1,630.00. Over the past decade, Lyell Immunopharma's PS Ratio has ranged from 5.83 to 14,490.00. According to the industry distribution chart, Lyell Immunopharma ranks #925 out of 930 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Lyell Immunopharma's PS Ratio too high?
Lyell Immunopharma's current PS Ratio of 6,860.00 is 321% above median its 10-year median of 1,630.00. Over the past 10 years, this metric has ranged from a low of 5.83 to a high of 14,490.00. The Biotechnology industry median PS Ratio is 8.89. Lyell Immunopharma's value of 6,860.00 is 77065.4% above this industry median. Based on the distribution chart, Lyell Immunopharma ranks #925 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyell Immunopharma has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's PS Ratio compare to ZNTL and PROK?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #925 out of 930 companies for PS Ratio. This places Lyell Immunopharma in the lower half of its industry. The industry median PS Ratio is 8.89. Lyell Immunopharma's value of 6,860.00 is 77065.4% above this benchmark. Historically, Lyell Immunopharma's own PS Ratio has ranged from 5.83 to 14,490.00 over the past decade. While the company's 10-year median is 1,630.00 vs. the industry median of 8.89, Lyell Immunopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.89, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyell Immunopharma's current PS Ratio of 6,860.00 is 77065.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lyell Immunopharma and its competitors. For the Biotechnology industry, the median PS Ratio is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyell Immunopharma's current PS Ratio is 6,860.00, which is 321% above median its own 10-year median of 1,630.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.24, compared to a current price of $13.72 — trading 161.8% above its estimated fair value. The current PS Ratio is 6,860.00, which is 321% above median its 10-year median of 1,630.00 and 77065.4% above the Biotechnology industry median of 8.89. Lyell Immunopharma's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current PS Ratio is 6,860.00 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $13.72 is trading 161.8% above its estimated GF Value™ of $5.24.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
PS Ratio: 6,860.00 (321% above median its 10-year median of 1,630.00)
GF Value™: $5.24 vs. price of $13.72 (161.8% above fair value)
Industry Position: 77065.4% above the Biotechnology median (#925 of 930)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
53GF Score
Get the complete analysis for LYEL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
